Gilead Sciences Inc. (GILD)

69.70
NASDAQ : Health Technology
Prev Close 67.00
Day Low/High 66.81 / 69.78
52 Wk Low/High 60.89 / 71.19
Avg Volume 9.51M
Exchange NASDAQ
Shares Outstanding 1.27B
Market Cap 84.82B
EPS 4.20
P/E Ratio 15.88
Div & Yield 2.72 (3.74%)
Cramer: There Should Be More Takeovers Where These Came From

Cramer: There Should Be More Takeovers Where These Came From

Buying's good for the acquirers, which should give other companies ideas.

Gilead Sciences Breaks Out

Gilead Sciences Breaks Out

With stock back up to $80, it's time to adjust the parameters.

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Prospects for acquisition activity in the sector are improving.

Cramer: Rebuilding After Hurricane Harvey Will Be Faster Than After Katrina

Cramer: Rebuilding After Hurricane Harvey Will Be Faster Than After Katrina

That would mean that there is the chance for a comeback here of some note.

Bears Still Can't Execute in the 'Red Zone'

Bears Still Can't Execute in the 'Red Zone'

Monday's action failed to change the overall character of the market

My Takeaways and Observations

"Yeah, well, that's just, like, your opinion, man." -- The Dude, The Big Lebowski Strikes and gutters today -- in a market characterized by winners and losers and weakening breadth. Ups and downs.    Amazon's shares may be signaling there is no fun,...

Cramer: Harvey's Not an Issue for the Markets, the iPhone Is

Cramer: Harvey's Not an Issue for the Markets, the iPhone Is

This market is focused on Apple and Gilead's planned acquisition of Kite.

Jim Cramer on Expedia, Uber, General Electric, Procter & Gamble, Western Digital, Gilead Sciences, Kite Pharma, Apple, Amazon, Whole Foods and Best Buy

Jim Cramer on Expedia, Uber, General Electric, Procter & Gamble, Western Digital, Gilead Sciences, Kite Pharma, Apple, Amazon, Whole Foods and Best Buy

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Monday's trending stocks

Gilead's Gain on Kite Acquisition Doesn't Make Sense

For the life of me I don't see why Gilead Sciences'  shares should respond very positively to the $13 billion acquisition of Kite Pharmaceutical . On Fast Money it is being argued that the takeover is anti-dilutive against cash. So what? It signals ...

Jim Cramer Reacts to the Gilead Sciences-Kite Pharma Acquisition

Jim Cramer Reacts to the Gilead Sciences-Kite Pharma Acquisition

Gilead is acquiring Kite Pharma.

Kite Takeover by Gilead Lifts Biotech Stocks

Kite Takeover by Gilead Lifts Biotech Stocks

The key to dealing with this environment is to keep an open mind.

After a Long Absence, the Gilead Bull Is Back

After a Long Absence, the Gilead Bull Is Back

In the past three months, prices have bottomed.

Here's Why I'm Valuing Value Over Growth

Here's Why I'm Valuing Value Over Growth

Multiples have become quite rich and dysfunction in Washington could end up biting the markets.

Gilead Solidly Higher; Markets in Narrow Range

Markets continue to trade in a very narrow range this Friday, commentary on the Daily Diary is certainly more active than equities today! Most major indices remain slightly down as they have been pretty much since the opening bell. The Dow has just ...

Biotech Bucking the Trend

Coming up on the two-hour mark on trading. The market is down slightly down across the board, with Nasdaq being affected by disappointing results from Starbucks and Amazon . The failure to even getting a "skinny" repeal and replacement of the Afford...

Now Up to the Plate, Today's Pinch Hitter, Bret Jensen!

It is good to be sitting in for Doug Kass here on the Daily Diary as we look to end the trading week on a positive note. It is also good to see the Yankees start to win close games again after losing so many of them in the weeks leading into the All...

Another Day - Another Busy Slate of Earnings

Another Day - Another Busy Slate of Earnings

Ford Motor Co. leads a list of notable earnings reports being released throughout the day on Wednesday

The Worm Has Turned in Biotech's Favor

The Worm Has Turned in Biotech's Favor

But this needs to heat up again for the sector to rally in a big way.

The Worm Has Turned in Biotech's Favor

The Worm Has Turned in Biotech's Favor

However, it will take acquisition activity to heat up again for the sector to rally in a big way.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

If Hedge Funds Are Selling These 3 Huge Stocks - Should You?

If Hedge Funds Are Selling These 3 Huge Stocks - Should You?

The pros hate these three big names, but there's reason to believe they got one wrong.

These Stocks Are Changing Course

These Stocks Are Changing Course

Bullish and bearish reversals for this week.

2 Recovering Biotech Names With Room to Run

2 Recovering Biotech Names With Room to Run

There are reasons to believe rallies in BioDelivery Sciences and Flexion Therapeutics should continue.

The Market Advance Narrows

"For a day where the S&P was essentially flat, there was a lot going on beneath the surface. Just a few days ago, everyone was so excited about the rally, but I pointed out that the cumulative advance/decline line (breadth) had not made a higher hig...

Cramer: Today's Market Emotion - Group Hug!

Cramer: Today's Market Emotion - Group Hug!

Banks, tech and healthcare are all seeing renewed buying.

Takeaways and Observations

  Top 10 Reasons the Lambs May Be Sheared ... or Slaughtered.    Stated simply, I see a trend change.   Hello uncertainty and volatility.    My pledge to all of the subs.    No, the tech selloff is not healthy and may not be an opportunity.  And som...

Today's Takeaways and Observations (Afternoon Edition)

"How does it feel, how does it feel? To be without a home Like a complete unknown, like a rolling stone." -- Bob Dylan, Like A Rolling Stone  "The Edifice Complex."   The message of the bond market is clear -- slowing inflation, economic growth and ...

The Good, the Bad and the Ugly (Boring Edition)

"There are two kinds of spurs, my friend. Those that come in by the door; those that come in by the window.." -- Tuco, " The Good, the Bad and the Ugly" No "Takeaways" today as the action was kinda boring, uneventful and with little individual stock...